These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 26645082)

  • 1. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.
    Lechner C; Baumann M; Hennes EM; Schanda K; Marquard K; Karenfort M; Leiz S; Pohl D; Venkateswaran S; Pritsch M; Koch J; Schimmel M; Häusler M; Klein A; Blaschek A; Thiels C; Lücke T; Gruber-Sedlmayr U; Kornek B; Hahn A; Leypoldt F; Sandrieser T; Gallwitz H; Stoffels J; Korenke C; Reindl M; Rostásy K
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):897-905. PubMed ID: 26645082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
    Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
    J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
    Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
    Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.
    Cobo-Calvo Á; Sepúlveda M; Bernard-Valnet R; Ruiz A; Brassat D; Martínez-Yélamos S; Saiz A; Marignier R
    Mult Scler; 2016 Mar; 22(3):312-9. PubMed ID: 26209592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
    Kitley J; Leite MI; Küker W; Quaghebeur G; George J; Waters P; Woodhall M; Vincent A; Palace J
    JAMA Neurol; 2013 Nov; 70(11):1375-81. PubMed ID: 23999580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis.
    Hyun JW; Kim SH; Huh SY; Kim W; Yun J; Joung A; Sato DK; Fujihara K; Kim HJ
    Mult Scler; 2015 May; 21(6):710-7. PubMed ID: 25305252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
    Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
    Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies.
    Chang KH; Lyu RK; Chen CM; Wu YR; Chang HS; Huang CC; Kuo HC; Chu CC; Hsu WC; Ro LS
    Mult Scler; 2013 Mar; 19(3):299-307. PubMed ID: 22829325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.